Delta-2: a phase 1, open-label, multicenter study of itil-168, an autologous tumorinfiltrating lymphocyte (til) cell therapy, with pembrolizumab in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts（2022）
关键词
pembrolizumab,lymphocyte,cell therapy,open-label,tumor-infiltrating
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要